It is unclear why a cluster randomised controlled trial design was not used, to avoid contamination between intervention and control patients recruited by the same pharmacy. The risk of contamination is not discussed as a limitation. It is possible that this contamination contributed to the negative study outcome, because although the control patients did not receive the medication review intervention, they were managed by the same community pharmacists (and possibly the same GPs) as the matched intervention patients. The pharmacists (and GPs) would have had increased awareness of, and focus on, the need to minimise use of anticholinergic and sedatives drugs, which might have impacted on the control patients.
The other important limitation that might have contributed to the negative outcome is the short follow-up. As the authors noted, it can take longer than three months for medication changes to be implemented following a medication review, for a variety of reasons. There could be a delay from recruitment/baseline to medication review, then to discussion between pharmacist and doctor, then to patient review by the doctor, then implementation of deprescribing. It would be helpful to know how long the delays were from baseline to medication review and to pharmacist-doctor discussion. Most sedative and anticholinergic drugs need to be stopped gradually, and usually only one such drug should be stopped at a time, which further contributes to delays in deprescribing. The authors have acknowledged that short follow up was a limitation, but I feel this requires further explanation/discussion.
There may also have been selection bias in the recruitment process, given that 67% approached patients did not agree to participate.
In the Background section it is stated that "a medication review is a structured assessment of a patient's medication by the community pharmacist ......". The reference is a Dutch one. Not all medication reviews, in all countries, are conducted by community pharmacists. Hence the definition needs to either be changed, or it needs to be clarified that this definition applies specifically to the Netherlands or to this study.
Review by an independent pharmacist, or a pharmacist co-located in the GP clinic, might be more effective than review by the patients' community pharmacist. There is some evidence that the latter approach results in better uptake of pharmacist recommendations.
In the Methods, more detail is required regarding the statement that "Pharmacists were experienced in performing medication reviews and had established working collaboration with GPs in the area". What were the minimum qualifications for the pharmacists, and how was 'experienced' defined? What is meant by "established working collaboration"? In the published protocol it mentions that the pharmacists were 'accredited', but this is not mentioned in the current manuscript. What does this accreditation entail, and if it is relevant it should be mentioned in this manuscript.
It is stated that the researchers were blinded to group allocation. How was blinding maintained when they collected data from the patients? It is likely that some patients would inadvertently reveal whether or not they had a medication review.
Page 5: I'm not familiar with the term 'pharmacotherapeutical'. Should this be 'pharmacotherapeutic'?
It would be helpful to have more information about the medication review process. -It is unclear whether the pharmacists had access to the patient's medical records when conducting the medication review. It seems they did not. If they did not, this is an important limitation and should be noted. -How many recommendations were made by pharmacists regarding DBI medications? -What % of recommendations were accepted or implemented? -Did the pharmacists sometimes recommend starting a new medication? This data may help to explain why there was no significant change in DBI In the previously published protocol it was stated that "generalised linear mixed models would be used to account for dependence of data (patients with pharmacy)". However in the submitted manuscript a different model was used for the primary outcome "as the intraclass coefficient was not significant."
Could the phrases "first analysis" and "second analysis" be renamed, e.g. intention to treat and per-protocol analysis? These terms were used in the protocol, and would be clearer for readers.
On page 12, Conclusion and implications, it would be worth noting that it may be the medication review model that is not effective, rather than multidisciplinary medication review per se. As the authors noted earlier, the pharmacists were busy and had competing priorities, and thus they didn't necessarily follow the recommended medication review protocol, for example by not discussing the medication review findings with the GPs, instead relying on email, etc. If the pharmacists didn't have access to the patients' medical histories this is also a limitation of the model. Abstract: The conclusion section of the abstract should indicated that medication review by a community pharmacist was not effective within 3 months of review, rather than just "medication review is not effective". (also use past tense)
REVIEWER
Anne Spinewine Université catholique de Louvain, Belgium REVIEW RETURNED 21-Sep-2017
GENERAL COMMENTS
The paper describes the results of a randomized controlled trial of medication review on the burden of anticholinergic and sedative medications, as measured by the DBI. This is a sound and wellconducted study. The paper is clearly written and the description of the method and results is concordant with the protocol that was published in 2015.
Introduction: I have no specific comment or request on this part.
Method: I have no major comment to share. Only a few questions:
How were pharmacists recruited? Was the sample more a convenient sample or a purposive sample? In other words, how representative was this sample of pharmacists? -It is mentioned that pharmacists are experienced in performing medication review, but the level of medication review is not clearly specified. I did not find a clear information on this in the protocol paper either. My question is what information on comorbidities, clinical data (past medical history and current diseases) was available to pharmacists? From the protocol paper, I understand that this information was either not available or not used. Is this correct? If so, could this be one of the reasons of the lack of effect (ie some recommendations made by the pharmacists may have been judged inappropriate by the GP, considering past and current medical history? -On p5, it is mentioned that pharmacists were requested to focus on anticholinergic and sedative medications. Were they provided specific material on this topic? (eg recommendations on the use and deprescribing of sedatives or antipsychotics) -Statistical analysis: in the first sentence, the authors could refer to "ITT" and "per-protocol" analyses.
Results: this section focuses on reporting the results on the primary and secondary outcomes listed in the methods section, which makes sense. However, in order to gain a better understanding of what happened (or did not happen) and of patients' characteristics, the paper would really benefit from more detailed information (this is my main comment for the results section). The following information would, in my opinion, be helpful: 
This is the first randomized controlled trial that compared the proportion of patients with decrease of DBI≥0.5 between control and intervention group, where the intervention was medication review by pharmacist in consultation with patient's GP. Although they did not see the result for the primary objective, I think the paper is wellwritten overall. There are some minor errors that need to be addressed and I am concerned that statistical analysis methods utilized is not very clear from tables in the results section.
Sample size calculation 1. Medium effect size was considered and used to calculate the sample size calculation using Cohen's (1992) method. I see Cohen provided a table for two-sided alpha and noticed that authors used one-sided alpha. Please confirm whether the one-sided alpha was used for the sample size calculation. 2. Because the sample size calculation was made based on no available information, it would be nice to have discussion on whether the effect size authors chose for the sample size calculation (0.5) was appropriate in the context of this study. For example, when I calculate the sensitivity assuming the proportion of 0.159 for the control group, with 80 subjects in each group, 80% power and twosided alpha of 0.05, intervention group would be required to have proportion ≥ 0.362. Is it reasonable to expect 36% of patients in intervention group would cease at least 1 drug? Also, did you expect such a high proportion of patients in control group to have decrease in DBI?
Statistical analysis 3. Please add "effects" where the term "mixed model" is used so it refers to the correct term "mixed effects model". Missing data: 14. There are 12 patients lost to follow-up in total, however, missing data for only 10 patients were explained in text. Please explain how you handled missing data for 2 patients not explained. 15. It seems there is unbalance in the number of lost to follow-up. Was it expected that less patients would be lost to follow-up in control group because they would get the intervention at the end of study rather than at the beginning of the study? Please discuss whether or not there was different in patients characteristics in those who were lost to follow up between intervention and control groups. 16. I suggest authors to split boxes for first and second analysis sets so that it is easier to follow which set of patients were excluded for the second analysis. 17. This figure contains errors, the number of patients included in the first analysis set for the intervention group is 75 (80 allocated minus 5 who were withdrawn before baseline) not 65. 18. The box shows "Lost to follow-up (2)" should be located between first analysis set and second analysis set to make it clear 2 patients lost to follow-up are of 82 patients included in the first analysis. This is a well-written manuscript. It reports that medication review by a community pharmacist did not reduce Drug Burden Index (DBI) over a 3-month follow-up period. Despite the lack of effect on DBI, there were significant improvements in two secondary outcome measures, although given the large number of secondary outcome measures (especially measures of cognition), perhaps this was a chance finding.
• It is unclear why a cluster randomised controlled trial design was not used, to avoid contamination between intervention and control patients recruited by the same pharmacy. The risk of contamination is not discussed as a limitation. It is possible that this contamination contributed to the negative study outcome, because although the control patients did not receive the medication review intervention, they were managed by the same community pharmacists (and possibly the same GPs) as the matched intervention patients. The pharmacists (and GPs) would have had increased awareness of, and focus on, the need to minimise use of anticholinergic and sedatives drugs, which might have impacted on the control patients.
Author answer: We have added the risk of contamination to the limitations in the discussion section on page 12: 'Firstly, our study design might have introduced a risk of contamination between intervention-and control arm, as pharmacists and GPs could have been triggered to optimize medication use also for patients in the control arm during the study period. We know from the pharmacists that no structured medication reviews were performed for control patients during the study period. Therefore we believe that changes we observed in control patients were due to usual care. Cluster randomization may have prevented the chance of contamination, but this method has other disadvantages.'
• The other important limitation that might have contributed to the negative outcome is the short follow-up. As the authors noted, it can take longer than three months for medication changes to be implemented following a medication review, for a variety of reasons. There could be a delay from recruitment/baseline to medication review, then to discussion between pharmacist and doctor, then to patient review by the doctor, then implementation of deprescribing. It would be helpful to know how long the delays were from baseline to medication review and to pharmacist-doctor discussion. Most sedative and anticholinergic drugs need to be stopped gradually, and usually only one such drug should be stopped at a time, which further contributes to delays in deprescribing. The authors have acknowledged that short follow up was a limitation, but I feel this requires further explanation/discussion.
Author answer: It was outside the scope of the study to collect more detailed information on the process of the medication reviews including time delays per medication review step. We believe a 3-months follow-up was suitable. We have added the following information to the methods section, page 6: 'We chose a 3-months follow-up because this was a reasonable time frame to detect medication changes by the medication review. A longer follow-up would have increased the chance of medication changes due to other reasons, such as changes in disease status.' Furthermore, we have elaborated in the discussion limitation section on page 12 as follows: 'One could suggest that more time was needed to determine the effect of the intervention, as changes in medication use may require more time, for example withdrawing of medication by step-wise reduction of dosing. However, there did not seem to be a difference in dosage changes between interventionand control arm.'
• There may also have been selection bias in the recruitment process, given that 67% approached patients did not agree to participate.
Author answer: We have added the following information to the limitations section on page 12: '.. one third of all eligible patients were willing to participate in the study. Given the frailty of this population and the time consuming nature of participation, we think this is a very reasonable response rate. Nevertheless, our results may not be generalizable to the total population.'
• In the Background section it is stated that "a medication review is a structured assessment of a patient's medication by the community pharmacist ......". The reference is a Dutch one. Not all medication reviews, in all countries, are conducted by community pharmacists. Hence the definition needs to either be changed, or it needs to be clarified that this definition applies specifically to the Netherlands or to this study.
Author answer: We have changed the sentence on page 4 to: 'In most countries a medication review is a structured assessment of a patient's medication, performed by the community pharmacist and/or general practitioner (GP), in order to optimize prescribing.'
• Review by an independent pharmacist, or a pharmacist co-located in the GP clinic, might be more effective than review by the patients' community pharmacist. There is some evidence that the latter approach results in better uptake of pharmacist recommendations.
Author answer: We have added this suggestion to the conclusion on page 13: 'This approach may be suitable for other patient groups and in other settings such as nursing homes or GP practices with colocated pharmacist.'
• In the Methods, more detail is required regarding the statement that "Pharmacists were experienced in performing medication reviews and had established working collaboration with GPs in the area". What were the minimum qualifications for the pharmacists, and how was 'experienced' defined? What is meant by "established working collaboration"? In the published protocol it mentions that the pharmacists were 'accredited', but this is not mentioned in the current manuscript. What does this accreditation entail, and if it is relevant it should be mentioned in this manuscript.
Author answer: We have elaborated on these questions in the study setting on page 5: 'One pharmacist per pharmacy was involved in the study. In Dutch community pharmacy practice, all registered pharmacists are allowed to perform medication reviews. Furthermore, pharmacists collaborate with GPs in their area. This includes local regular meetings of pharmacists and GPs in pharmacotherapy counselling groups. In the Netherlands, each individual is registered with a single pharmacy. Pharmacies hold a complete electronic medication history for each patient registered with them. When undertaking a medication review the pharmacists may request the patients' medical records from the GP. At the time of the study, all Dutch community pharmacists were required to perform medication reviews in cooperation with the GP for high risk patients according to the guidelines.'
• It is stated that the researchers were blinded to group allocation. How was blinding maintained when they collected data from the patients? It is likely that some patients would inadvertently reveal whether or not they had a medication review.
Author answer: We added the following information to the manuscript on page 5: 'Pharmacists and patients could not be kept blind, but were explicitly asked not to reveal study allocation for individual patients to the researchers who collected the data.'
• Page 5: I'm not familiar with the term 'pharmacotherapeutical'. Should this be 'pharmacotherapeutic'?
Author answer: Thank you, we rephrased as 'pharmacotherapeutic'.
• It would be helpful to have more information about the medication review process.
Author answer: We have elaborated on the community pharmacy setting on page 4 and 5 as described above. Furthermore we have elaborated on this in the intervention section on page 5 and 6: '
Step one is a face-to-face consultation between the pharmacist and patient to discuss medication use. Second, the pharmacist undertakes a pharmacotherapeutic medication review, identifying potential pharmacotherapeutic problems and drafting written recommendations for medication optimisation to discuss with the patients' GP. Third, a multidisciplinary meeting, between pharmacist and GP is held. At this meeting, the potential medication problems of the patient are discussed and draft of a pharmacotherapeutic action plan is decided. Fourth, a discussion of the draft pharmacotherapeutic action plan between patient and pharmacist and/or GP. The patients' expectations and wishes are key elements in the decision-making process and are included in the final action plan. Fifth, a follow-up of the final pharmacotherapeutic action plan is undertaken. Further detail of the medication review process and the Dutch guideline underpinning the study can be found in our previously published study protocol.'
• It is unclear whether the pharmacists had access to the patient's medical records when conducting the medication review. It seems they did not. If they did not, this is an important limitation and should be noted.
Author answer: We have elaborated on this question in the study setting on page 5: 'One pharmacist per pharmacy was involved in the study. In Dutch community pharmacy practice, all registered pharmacists are allowed to perform medication reviews. Furthermore, pharmacists collaborate with GPs in their area. This includes local regular meetings of pharmacists and GPs in pharmacotherapy counselling groups. In the Netherlands, each individual is registered with a single pharmacy.
Pharmacies hold a complete electronic medication history for each patient registered with them. When undertaking a medication review the pharmacists may request the patients' medical records from the GP. At the time of the study, all Dutch community pharmacists were required to perform medication reviews in cooperation with the GP for high risk patients according to the guidelines.'
• How many recommendations were made by pharmacists regarding DBI medications?
Author answer: It was outside the scope of our study to collect more detailed data on the changes recommended by the pharmacists. But we have added a table (appendix 3) containing a detailed description on the number of patients who had medications started, stopped and changed in dose at follow-up in intervention-and control arm.
• What % of recommendations were accepted or implemented?
Author answer: See previous reply.
• Did the pharmacists sometimes recommend starting a new medication? This data may help to explain why there was no significant change in DBI.
• In the previously published protocol it was stated that "generalised linear mixed models would be used to account for dependence of data (patients with pharmacy)". However in the submitted manuscript a different model was used for the primary outcome "as the intraclass coefficient was not significant."
Author answer: We have elaborated on the statistics section on page 7 to make this more clear: 'For the analysis of the primary outcome, we initially considered a generalized linear mixed effects model to adjust for dependence of observations (i.e. clustering of patients within pharmacies). However, as the intra-class correlation was not significant and no significant clustering was observed, extension of the model with random effects at the level of pharmacies was not necessary. Therefore, only fixed effects were considered and standard fixed effects logistic regression model applied.'
• Could the phrases "first analysis" and "second analysis" be re-named, e.g. intention to treat and perprotocol analysis? These terms were used in the protocol, and would be clearer for readers.
Author answer: Thank you for your comment. We chose these phrases as we were advised that the CONSORT statement has dropped the names 'intention to treat' and 'per protocol' "in favour of a clear description of exactly who was included in which analysis" (http://www.consortstatement.org/checklists/view/32--consort-2010/96-statistical-methods).
• On page 12, Conclusion and implications, it would be worth noting that it may be the medication review model that is not effective, rather than multidisciplinary medication review per se. As the authors noted earlier, the pharmacists were busy and had competing priorities, and thus they didn't necessarily follow the recommended medication review protocol, for example by not discussing the medication review findings with the GPs, instead relying on email, etc. If the pharmacists didn't have access to the patients' medical histories this is also a limitation of the model.
Author answer: We have included more details on the setting and the possible limitations and implications of our study as outlined above. This should help readers to better understand the intervention and the context of our study. We have also modified the implication section to address the reviewer's suggestion as follows on page 13: 'Pharmacist-led medication review as currently performed in the Netherlands did not appear effective in reducing the DBI. Despite some practical issues with the DBI, such as the lack of an international consensus-based list of anticholinergic/sedative medication including minimum doses, we suggest to use the DBI as a tool to identify harmful medication users. This approach may be suitable for other patient groups and in other settings such as nursing homes or GP practice with co-located pharmacist.'
• Abstract: The conclusion section of the abstract should indicated that medication review by a community pharmacist was not effective within 3 months of review, rather than just "medication review is not effective". (also use past tense) The paper describes the results of a randomized controlled trial of medication review on the burden of anticholinergic and sedative medications, as measured by the DBI. This is a sound and well conducted study. The paper is clearly written and the description of the method and results is concordant with the protocol that was published in 2015.
• How were pharmacists recruited? Was the sample more a convenient sample or a purposive sample? In other words, how representative was this sample of pharmacists?
Author answer: We have added information to the following sentence on page 4/5 to make it clearer: 'Pharmacies were recruited via the regional association of pharmacists and participation was voluntary. One pharmacist per pharmacy was involved in the study.'
• It is mentioned that pharmacists are experienced in performing medication review, but the level of medication review is not clearly specified. I did not find a clear information on this in the protocol paper either. My question is what information on comorbidities, clinical data (past medical history and current diseases) was available to pharmacists? From the protocol paper, I understand that this information was either not available or not used. Is this correct? If so, could this be one of the reasons of the lack of effect (ie some recommendations made by the pharmacists may have been judged inappropriate by the GP, considering past and current medical history?
• On p5, it is mentioned that pharmacists were requested to focus on anticholinergic and sedative medications. Were they provided specific material on this topic? (eg recommendations on the use and deprescribing of sedatives or antipsychotics)
Author answer: We have elaborated on this in the intervention section on page 6: 'The pharmacists participating in the study all undertook regular medication reviews as part of their practice and as such were familiar with the guideline. Nonetheless, we provided the guidelines to the pharmacists with the request to focus on anticholinergic and sedative medications. No additional educational material on anticholinergic and sedative medication was provided.'
• Statistical analysis: in the first sentence, the authors could refer to "ITT" and "per-protocol" analyses.
Results: this section focuses on reporting the results on the primary and secondary outcomes listed in the methods section, which makes sense. However, in order to gain a better understanding of what happened (or did not happen) and of patients' characteristics, the paper would really benefit from more detailed information (this is my main comment for the results section). The following information would, in my opinion, be helpful:
• Table 1 (+table2): o additional information on anticholinergic drugs and sedatives should be presented, as currently we only have drug use per ATC1 level (which is not very informative, in my opinion), and the mean+/-SD for the DBI. These more detailed data should also be presented at 3 months. This would give the reader a better idea of whether there have been some modifications in specific classes of drugs, when classes are looked at separately.
Author answer: We have added a table (appendix 3) containing a detailed description on the number of patients who had medications started, stopped and changed in dose at follow-up in interventionand control arm.
o Clinical information -if available -should be presented: prevalence of some comorbidities that are important when it comes to anticholinergic and sedative drugs (eg previous fall, psychiatric condition, depression, cognitive impairment,…). If such data is not available, authors may need to discuss this in the limitations section.
Author answer: Thank you for this suggestion. We concur. This is why we collected a number of patient relevant outcomes which are validated neuropsychological tests of cognitive impairment and performance tests of physical function indicative of e.g. fall risk. Please refer to Table 3 . Pharmacists were able to request medical records for the medication review from the GP, as mentioned above.
• Additional comments: o P9, l28: "a higher proportion" sound as an overstatement, considering that the differences are minor, i.e. 17.3% vs 15.9%, OR 1.04, p=0.927. "the proportion of … did not differ" may be more appropriate.
Author answer: We have changed the sentence on page 9 to: 'In the first analysis, which included all patients with a baseline measurement, the proportion of patients with a decrease of DBI ≥0.5 did not differ between patients in intervention-and control group (17.3% to 15.9%, OR 1.04, CI 0.47 to 2.64, p=0.927).' o Table 3 : as several of the scales used are not frequently used in reports on medication review, it may be useful for readers to have additional information on the scales (nb of items, range for scores, and, when possible, what would be considered a clinical significant difference). This might be presented in an appendix.
Author answer: Thank you for this suggestion. We have added a table with information on secondary outcome distributions and how we handled these data (appendix 1).
o Even though the number of patients is limited, the prevalence of falls seems to be higher in intervention as compared to control group (28.4% vs 19.5%). Do the authors have some explanations, or hypotheses to share/discuss? In contrast, unplanned hospital admissions are less frequent in the intervention group. Would the authors have the possibility to evaluate the 9+3 admissions (using discharge reports, for example), to evaluate whether these admissions could have been drugrelated?
Author answer: While it appears that there were more falls in term of absolute numbers, the differences in both falls and hospital admissions were not statistically significant, and so no secondary analysis of these were conducted.
Discussion
• On p11, the authors mention that fidelity to the intervention may not have been high (for face-to-face meetings. This question may be more appropriate for the results section, but do authors have more information on the DRPs identified by pharmacists, on the interventions/recommendations made to GPs (how many, what kind of intervention), and finally on the acceptance rate by GPs? In other words, have the authors conducted a process evaluation, that would help in understanding what the intervention didn't work as expected? If this has not been performed, then it should be added as a limitation.
Author answer: It was outside the scope of our study to collect more detailed data on the changes recommended by the pharmacists. But we have added a table (appendix 3) containing a detailed description on the number of patients who had medications started, stopped and changed in dose at follow-up in intervention-and control arm. For the process evaluation please see below our answer to your last comment.
• Limitations: o A substantial proportion of eligible participants refused to participate. How does this affect the external validity of the study?
Author answer: We have added the following information to the limitations section on page 12: 'Finally, one third of all eligible patients were willing to participate in the study. Given the frailty of this population and the time consuming nature of participation, we think this is a very reasonable response rate. Nevertheless, our results may not be generalizable to the total population.' o qualitative approach, in-depth process evaluation is missing Author answer: Thank you for this suggestion, it would have been very interesting to have these data but it was outside the scope of our study to perform an in-depth process evaluation. We have elaborated on this in the limitation section on page 12: 'Second, although we did check whether all steps of the medication review were conducted, it was outside the scope of our study to investigate to what extent pharmacists adhered to communication methods recommended by the guideline on performing the medication review. Informal conversations with pharmacists suggested that although the guidelines recommend a face-to-face meeting between the pharmacist and GP, some pharmacists contacted the GP by phone, fax, or email due to lack of time. This might have had an effect on the implementation of medication suggestions. A full process evaluation might have given insight in this, but also might have changed the normal practice of pharmacists to carry out medication reviews. We believe that our results reflect "real-world" practice of how medication reviews were carried out in Dutch health care practice at the time of the study. Please leave your comments for the authors below This is the first randomized controlled trial that compared the proportion of patients with decrease of DBI≥0.5 between control and intervention group, where the intervention was medication review by pharmacist in consultation with patient's GP. Although they did not see the result for the primary objective, I think the paper is well-written overall. There are some minor errors that need to be addressed and I am concerned that statistical analysis methods utilized is not very clear from tables in the results section.
Sample size calculation 1. Medium effect size was considered and used to calculate the sample size calculation using Cohen's (1992) method. I see Cohen provided a table for two-sided alpha and noticed that authors used one-sided alpha. Please confirm whether the one-sided alpha was used for the sample size calculation.
Author answer: We thank the reviewer for detecting this inconsistency. We indeed calculated the sample size using the two-sided alpha as outlined by Cohen in his Power Primer in Psychological Bulletin in 1992. In line with this, statistical tests need to be two-sided as well. Two-sided testing is indeed more sound as it permits a poorer outcome for the intervention (c.f. the HOMER trial by Holland et al., BMJ, 2005 who actually found medication reviews to result in a significantly increased rate of hospital admissions. Please note that the P-value associated with our primary outcome equalled 0.927. Hence, the interpretation is similar if a one-sided alpha of 5% or a two-sided alpha of 5% (with 2.5% for the left and 2.5% for the right tail) is considered.
2. Because the sample size calculation was made based on no available information, it would be nice to have discussion on whether the effect size authors chose for the sample size calculation (0.5) was appropriate in the context of this study. For example, when I calculate the sensitivity assuming the proportion of 0.159 for the control group, with 80 subjects in each group, 80% power and two-sided alpha of 0.05, intervention group would be required to have proportion ≥ 0.362. Is it reasonable to expect 36% of patients in intervention group would cease at least 1 drug? Also, did you expect such a high proportion of patients in control group to have decrease in DBI?
Author answer: Since to the best of our knowledge, only one pilot had been conducted by Gnjidic and colleagues in 2010 (see reference 10 in the manuscript), we could not base our sample size calculation on a number of previously conducted studies. We therefore adopted a different mode of reasoning as outlined in the sample size section on page 7. 'We chose a medium effect size as we considered a small effect size not to be clinically relevant and a power to detect a medium effect size also to be capable of detecting a large effect size.' After all you do not know the magnitude of your finding beforehand. We agree with the reviewer's doubts if a medium effect size is actually also reasonable. A tentative answer to the question whether it is reasonable to expect a rate of 36% of patients to cease ≥ 1 drugs is actually given by the pilot study of Gnjidic et al. At 3 months of follow-up (like in our study), a DBI change was observed in 32% of patients in the intervention group, and in 19% of patients in the control group. So 36% may actually not be unreasonable a priori. However, as can be inferred from Appendix 3 this rate was indeed actually lower in our study. A more definite answer will eventually be provided by conducting a dozen of replications that will also permit an individual patient data meta-analysis to arrive at an accurate stable estimate of the Effect Size.
Statistical analysis 3. Please add "effects" where the term "mixed model" is used so it refers to the correct term "mixed effects model".
Author answer: Please see our answer to your next question.
4. Please specify the statistical model used for the primary outcome variable. It is not clear whether the logistic mixed effects model with patient ID as random effect or conditional logistic regression model was used (i.e. patient ID as fixed effects).
Author answer: Thank you for your comment and apologies if this was not clear. After observing that there was no significant intra-class correlation of the pharmacies, we performed standard regression analysis (thus considering only fixed effects). We realize that using the term 'mixed effects model' is confusing, as in the end we applied a standard logistic regression. We have changed all 'mixed effects' to 'regression' in the manuscript.
5. Please revise "linear mixed model" as "generalised linear mixed effects model" in sentence "Most secondary outcomes were examined with linear mixed models." Please also make this correction in the abstract.
Author answer: We changed the name of the model to 'regression' as we only used fixed effects in the end, see explanation above.
Trailmaking Test A&B: as data is log transformed, geometric mean and standard deviations
Author answer: We agree with the reviewer where she says that from a statistical angle it would be more appropriate to present the geometric mean. However, to facilitate comparisons with neuropsychological studies which typically do not report geometric means, we have reported the actual mean and standard deviation. We have added a table (see appendix 1) with details of the secondary outcome scales.
7. GARS, EQ-5D, 7MS-Benton temporal orientation, 7MS-clock drawing and 7MS-enhanced cued recall tests: please specify whether logistic mixed effects model or conditional logistic regression model was used. If logistic mixed effects model was used, were both pharmacist and patient ID used as random effects?
Author answer: Please refer to explanation above. We hope that with adjusting the name of the analysis model, as described above, it is clear now in the manuscript.
8. It is not clear how these variables were treated and analysed: 7MS-verbal fluency test, sedative side effects, UKU, VAS and Up & Go
Author answer: Thank you for your comment and our apologies if this was not clear. We elaborated on this in the statistical methods for more clarity. Furthermore we made an appendix (see appendix 1) showing how all secondary outcome tests and -questionnaires were handled in our study.
9. How did you handle multiple falls and hospitalizations within a patient?
Author answer: We have added the following information to the statistical analysis section page 7/8 to clarify this: 'Reported falls, hospitalization and mortality were only assessed from patients with a follow-up measurement. These variables were dichotomized, reported as number and percentages of patients and analysed using Fisher's exact test.'
10. Sensitivity analysis on outliers are not presented.
Author answer: We have now reported a number of sensitivity analyses (see appendix table 2).
11. For secondary outcome variables: although number of medication at the baseline was significantly different between intervention and control groups, there was no significant difference in DBI between two groups at the baseline. I wonder whether a sensitivity analysis adjusting for the baseline DBI in place of the number of medication at the baseline would be useful?
Author answer: Please find below the results of this sensitivity analysis, it is also not significant.
Proportion with decrease of DBI ≥ 0.5 (%, n) Odds ratio (95% CI) * p-value Intervention Control Second analysis (n=145) 18.5 (12) 16.3 (13) 1.17 (0.48 to 2.82) 0.735 * Binary logistic regression, adjusted for age, gender, DBI at baseline. Second analysis: all patients who were not lost to follow-up, and who received the intervention as allocated 12. While the primary outcome variable was proportion of patients with DBI decreased more than 0.5 unit, there was no outcome variable explored the decrease in DBI as continuous variable. I wonder whether it would be useful measure as the dichotomous variable used as the primary outcome variable lose information that could be useful, so please provide explanation why the change in DBI was not considered as an outcome variable for this study.
Author answer: Please find below the results of the sensitivity analysis in which the DBI is treated as a continuous variable, it is also not significant. Missing data: 14. There are 12 patients lost to follow-up in total, however, missing data for only 10 patients were explained in text. Please explain how you handled missing data for 2 patients not explained.
Author answer: We believe there was a misunderstanding. We had only 2 patients who were lost to follow, not 12 patients. The 10 other patients were not lost to follow-up, but did not receive the intervention as allocated, therefore we had to exclude them from the secondary analysis.
In the missing data section we describe that we do not have follow-up data of the two patients who were lost to follow up, obviously. Then there were 8 other patients with whom we could not verify medication by phone.
We have changed the sentence in the missing data section on page 8, which hopefully makes it clearer: 'Of the two patients, who were lost to follow-up, the baseline observation for medication use was carried forward to follow-up.' Furthermore we have adjusted figure 1 due to your comments below.
15. It seems there is unbalance in the number of lost to follow-up. Was it expected that less patients would be lost to follow-up in control group because they would get the intervention at the end of study rather than at the beginning of the study? Please discuss whether or not there was different in patients characteristics in those who were lost to follow up between intervention and control groups.
Author answer: We believe there was a misunderstanding. We had only 2 patients who were lost to follow, not 12 patients. The 10 other patients were not lost to follow-up, but did not receive the intervention as allocated, therefore we had to exclude them from the secondary analysis. 16. I suggest authors to split boxes for first and second analysis sets so that it is easier to follow which set of patients were excluded for the second analysis.
Author answer: Thank you for this suggestion. We have made changes to figure 1, to make it more clear.
17. This figure contains errors, the number of patients included in the first analysis set for the intervention group is 75 (80 allocated minus 5 who were withdrawn before baseline) not 65.
Author answer: Thank you, we have changed this to 75.
18. The box shows "Lost to follow-up (2)" should be located between first analysis set and second analysis set to make it clear 2 patients lost to follow-up are of 82 patients included in the first analysis.
Author answer: Thank you for this suggestion. We have made changes to figure 1, to make it more clear. The paragraph before discussion section, starting "Of all 144 patients": 22. The number "144" should read 145.
Author answer: We have based the analysis of falls and hospitalization on the number of patients that had a follow-up meeting, this was 144 patients, regardless whether they were treated according to their allocation or not. We realize it is clearer to do this analysis also only on the patients included in the second analysis, therefore we adjusted the text in the results section on page 11 to: 'Reported falls and hospitalization could be assessed from 136 patients who were included in the second analysis. No significant difference was found in reported falls between control-and intervention group, respectively 15 patients (19.5%) versus 18 patients (30.5%), (p=0.100). There was also no difference found between control-and intervention arm in hospitalization, 9 (11.7%) versus 3 (5.1%) patients reported unplanned hospital admission, (p=0.149).' Author answer: The p-value was based on 15/77=0.195 and 18/67=0.305 as the total number was 144 patients who had a follow-up meeting. Our apologies if this was not clear. We have changed this part according to your comments, as described above.
VERSION 2 -REVIEW

REVIEWER
Rohan Elliott
Austin Health, Australia REVIEW RETURNED 21-Jan-2018
GENERAL COMMENTS
The authors have addressed most of my earlier comments, however I believe the following should be addressed:
* Background -The modified definition of 'medication review' now states that in most countries a medication is performed by a community pharmacist and/or GP. The reference is an unpublished Dutch guideline. This is not necessarily true, as medication reviews in countries such as the US and Australia are performed by consultant pharmacists who are often independent of the community pharmacy. The authors should also specify that they are referring to primary care, because in other settings medication reviews are regularly performed by others, for example, by hospital pharmacists, geriatricians, etc.
* Discussion -It is unfortunate that the authors did not collect data on the medication review process, for example the time between baseline and medication review / pharmacist-GP discussion. In practice, there can be significant delays in these processes, due to the logistical challenges associated with scheduling meetings with patients and GPs, and this may have been a factor in the negative outcome of this study, since the follow-up was only 3 months. Although the authors have justified in the Methods their choice of 3 months for follow-up, the lack of data regarding when the these potential time delays should be acknowledged in the limitations section.
* Discussion -The authors have clarified that pharmacists were able to request patients' medical records from GPs, but it seems that this was not a mandatory part of the medication review, and because no data was collected on the medication review process we do not know how often this occurred. Performing a medication review without access to patients' clinical data is likely to be ineffective. This needs to be clearly noted as a limitation. -In-depth process evaluation missing; this was one of my main comment, and several questions related to this. The paragraph added in the limitations section is fine, except for the part of the sentence underlined here: "a full process evaluation might have given insight in this, but also might have changed the normal practice of pharmacists to carry out medication reviews". There are various methods to conduct process evaluation, usually a combination of quantitative and qualitative approaches. If the research team had, for example, conducted interviews with pharmacists, GPs and patients after the end of the trial, to explore fidelity, mechanism of impact and context, this would have provided useful information without modifying practices during the trial. My request would be to delete this part of the sentence.
REVIEWER
-Comment on difference in fall incidence between both groups: the answer remains limited. I agree that the difference is not significant, but the study was not powered to detect a significant difference on this outcome. Given the size of the difference (10% absolute difference and 50% relative increase), this can be considered as a "signal" to be looked at in the future, and I think it is at least necessary to mention, in the perspectives section, that in further studies this will have to be analysed more in depth, as this is an important outcome for older people.
-Abstract: regarding secondary outcome measures, only the measures with a significant effect are reported; authors should mention that no effect or no difference was found for other measures VERSION 2 -AUTHOR RESPONSE Reviewer: 1 Reviewer Name: Rohan Elliott Institution and Country: Austin Health, Australia Please state any competing interests or state 'None declared': None declared Please leave your comments for the authors below The authors have addressed most of my earlier comments, however I believe the following should be addressed:
-Background -The modified definition of 'medication review' now states that in most countries a medication is performed by a community pharmacist and/or GP. The reference is an unpublished Dutch guideline. This is not necessarily true, as medication reviews in countries such as the US and Australia are performed by consultant pharmacists who are often independent of the community pharmacy. The authors should also specify that they are referring to primary care, because in other settings medication reviews are regularly performed by others, for example, by hospital pharmacists, geriatricians, etc.
We have adjusted the section to: "Two small Australian studies suggest that medication review could be a promising strategy in reducing the DBI in community dwelling older people. [9, 10] Medication review is 'a structured, critical examination of a person's medicines with the objective of reaching an agreement with the person about treatment, optimising the impact of medicines, minimising the number of medication related problems and reducing waste'.[11]" We have replaced reference 11 (which was the Dutch guideline) with a published English guideline.
-Discussion -It is unfortunate that the authors did not collect data on the medication review process, for example the time between baseline and medication review / pharmacist-GP discussion. In practice, there can be significant delays in these processes, due to the logistical challenges associated with scheduling meetings with patients and GPs, and this may have been a factor in the negative outcome of this study, since the follow-up was only 3 months. Although the authors have justified in the Methods their choice of 3 months for follow-up, the lack of data regarding when these potential time delays should be acknowledged in the limitations section.
We have added this point to the limitation section on page 12: "Third, we followed patients for three months after the intervention. Possibly, more time may have been necessary to determine the effect of the intervention. We were not able to collect data about timing of the medication review steps, so in some cases there may have been delay in performing all steps. But in Dutch primary care, pharmacists and GP's have an established close collaboration and therefore we believe that long delays were unlikely. Another argument for a longer follow-up could be that changes in medication use may require more time, for example withdrawing of medication by step-wise reduction of dosing. However, there did not seem to be a difference in dosage changes between intervention-and control arm." -Discussion -The authors have clarified that pharmacists were able to request patients' medical records from GPs, but it seems that this was not a mandatory part of the medication review, and because no data was collected on the medication review process we do not know how often this occurred. Performing a medication review without access to patients' clinical data is likely to be ineffective. This needs to be clearly noted as a limitation.
We added some extra information about the request of medical records in the method section and the limitations: -Study design, setting and participants, p. 5: "When undertaking a medication review it is routine practice of pharmacists to obtain an extensive summary of the electronic patients' medical records, including latest recorded episodes and lab-values, from the GP." -Intervention, p.6: "Second, the pharmacist undertook a pharmacotherapeutic medication review, identified potential pharmacotherapeutic problems taking into account the patient's medical records, including latest recorded episodes and lab-values (if available). Accordingly the pharmacist drafted written recommendations for medication optimisation to discuss with the patients' GP." -Strengths and limitations of the study, p. 12: "Second, although we did check whether all steps of the medication review were conducted, it was outside the scope of our study to investigate to what extent pharmacists adhered to methods recommended by the guideline on performing the medication review. … Furthermore, while as part of the established collaboration between pharmacists and GPs in Dutch primary care, Dutch pharmacists routinely request an extensive summary of the electronic patient's medical records from the GP to perform a medication review, it is possible that some pharmacists did not do this. We performed a pragmatic trial and therefore our results reflect "realworld" practice of how medication reviews were carried out in Dutch health care practice at the time of the study."
Also we added three references that describe the setting of Dutch community pharmacies, reference 23 and 24.
Reviewer: 2 Reviewer Name: Anne Spinewine Institution and Country: Université catholique de Louvain, Belgium Please state any competing interests or state 'None declared': None declared Please leave your comments for the authors below Revision v2 Thank you for the revision and point-to-point answers.
I am satisfied with most of the modifications done, but I still have a few issues: -Appendix 3: thank you for adding this table. The data from this table are not used to provide information in the results or discussion section. My question would be "what are you main observations/conclusions from the results in this table"? at least one additional sentence in the results section, and if useful some reference to these data in the discussion. For example, to me it seems that for none of the DBI drugs at ATC-level 1 classes and for none of the possible modifications (started, stopped, dose changes) substantial differences can be noted. One exception is the "dose change, CV drugs". Does this relate to one specific drug? If so which one?
We added the following to the results section on page 9: "Descriptive analysis showed medication changes (starting, stopping, dosage change) of DBI medications on ATC code level 1 in 53.8% of patients from intervention arm and in 45.0% of patients from control arm. For cardiovascular DBI medications, dose increases and -decreases of different medications occurred in 10.8% patients from intervention arm compared to 1.3% of patients from control arm (Appendix table 3)."
We amended the following part of the discussion on page 13: "The medication changes in both groups were comparable. Small changes in different therapeutic medication groups suggest fluctuations of medication use over time as prescribing is a dynamicrather than a static process. We do not know the pattern of fluctuations in anticholinergic and sedative medication prescribing; this should be explored in longitudinal studies powered to detect changes at medication level." -Appendix 1: Thank you for adding this table. My former comment also aimed to ensure understanding by any reader, so I would add -if possible -below the table for example a short description of each scale, what it intends to measure, and how to interpret it.
We have added the extra information in the table as suggested.
-In-depth process evaluation missing; this was one of my main comment, and several questions related to this. The paragraph added in the limitations section is fine, except for the part of the sentence underlined here: "a full process evaluation might have given insight in this, but also might have changed the normal practice of pharmacists to carry out medication reviews". There are various methods to conduct process evaluation, usually a combination of quantitative and qualitative approaches. If the research team had, for example, conducted interviews with pharmacists, GPs and patients after the end of the trial, to explore fidelity, mechanism of impact and context, this would have provided useful information without modifying practices during the trial. My request would be to delete this part of the sentence.
We deleted this sentence.
Thank you for this comment. We agree that patient-related outcomes are very important. We therefore added a sentence in the 'Conclusions and implications section' on page 13. We refer in this sentence to your paper: Beuscart et al. 2017 . "While our study was powered to detect a difference in medication use, it should be acknowledged that other patient outcomes, like geriatric syndromes (e.g. risk of falls) and adverse events (e.g. drugrelated hospital admission) are very important for the evaluation of medication review in older patients. Further studies should ensure sufficient sample sizes to study these outcomes." -Abstract: regarding secondary outcome measures, only the measures with a significant effect are reported; authors should mention that no effect or no difference was found for other measure Thank you, we have added a sentence stating that no difference was found in other secondary outcome measures.
VERSION 3 -REVIEW
REVIEWER
Anne Spinewine Université catholique de Louvain REVIEW RETURNED 23-Apr-2018
GENERAL COMMENTS
The authors have adequately addressed the second set of questions raised. The paper can be accepted for publication, in my opinion.
